Navigation Links
BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
Date:9/30/2009

NOVATO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 28, at 5:00 p.m. ET to discuss third quarter 2009 financial results.

    U.S. / Canada Dial-in Number:  800.299.6183
    International Dial-in Number:  617.801.9713
    Participant Code: 51404008
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 51416825

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development fo
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Present at the Morgan Stanley Healthcare Conference
2. BioMarin to Present at the Baird Healthcare Conference
3. BioMarin to Present at the Jefferies Healthcare Conference
4. BioMarin to Present at the Goldman Sachs Healthcare Conference
5. BioMarin to Present at the Deutsche Bank Health Care Conference
6. BioMarin to Present at the Baird Growth Stock Conference
7. BioMarin Announces First Quarter 2009 Financial Results
8. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
9. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
10. BioMarin to Present at the 4th Annual Citi Biotech Day
11. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... JUPITER, Fla. , Aug. 18, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... and other proteins for the bioenergy, bio-based chemical, ... it has filed a Registration Statement on Form ... (the "SEC"). Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... heat during the production of electricity could be ... via a technique developed by researchers with the ... Laboratory (Berkeley Lab) and the University of California ... this technology include DOEs hydrogen fuel cell-powered Freedom ...
... in the Philadelphia suburbs, with unique new capabilities enabled by Masimo ... ... technologies, IRVINE, Calif., Jan. 10 Abington Memorial,Hospital and ... & Low Perfusion Pulse Oximetry, have announced the,completion of Philadelphia-based Abington ...
... Ky., Lexington, Ky., and Newport News, Va. Also ... ... spirit of excellence and remarkable achievements in its,community, Harborview Medical Center of ... is one of the most esteemed,honors of excellence in community service in ...
Cached Biology Technology:Feeling the heat 2Feeling the heat 3Feeling the heat 4Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 2Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 3Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 5Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 6
(Date:8/18/2014)... Half of the Earth,s land mass is made ... they are being transformed at an alarming rate. Woody ... and taking over, leading to a loss of critical ... of ecosystems to produce food specifically meat. ... Sciences led an investigation that quantified this loss in ...
(Date:8/18/2014)... Researchers from Aarhus University, Denmark, and the University of Wisconsin-Madison, ... exposure of species to both climate and land use change. ... species in the face of combined rates of climate and ... , Their results, which have just been published in ... vulnerable to losses in biodiversity and ecosystem function due to ...
(Date:8/18/2014)... the pygmy phenotype is probably a selective adaptation ... of researchers, but all African pygmy phenotypes do ... more recent adaptation than previously thought., "I,m interested ... very challenging environments," said George H. Perry, assistant ... rainforests are difficult for humans to live in. ...
Breaking Biology News(10 mins):Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3The double threat of climate and land use change enhances risks to biodiversity 2Pygmy phenotype developed many times, adaptive to rainforest 2
... 28, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a ... drugs to treat diseases of aging, announced today that ... developed novel drug candidates that offer a promising, new ... Diabetes, by targeting SIRT1, a gene that controls the ...
... Although a high standard of morality gives but a ... his children over the other men of the same ... give an immense advantage to one tribe over another. ... an evolutionary explanation for morality and pro-social behaviors individuals ...
... able to form abstract concepts. Friederike Range and ... shown for the first time that dogs can classify ... the same way that humans do. And the ... computer automated touch-screens, eliminating potential human influence. The ...
Cached Biology News:Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 2Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 3Group selection, a theory whose time has come...again 2Computer savvy canines 2
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Biology Products: